TICKERNERD
Menu
ATTOHealthcare · Biotechnology

ATTO Stock Forecast: Attovia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$16
−0.67% on the day

The 5 Wall Street analysts covering Attovia Therapeutics, Inc. hold a median 12-month price target of $45 — +175.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$744.6M
Ticker Nerd rank
0 / 100
Median analyst target
$45
Analysts covering
5
Revenue$450K−99.9% y/y
Operating income−$21.8M
Net income−$20.7M
Free cash flow−$16.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.3%
1M
−31.1%
From high
−36.2%
From low
0.0%
$16
$26
Range since 5 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

ATTO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Attovia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
48
Revisions
30
Value
9
Growth
8
Accruals
8
Issuance
7
Quality
3
Volatility
1
Momentum
1

Size (48): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATTO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATTO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 5 Aug 2026Adjusted close, US dollars
$10$20$30$40$50Sep 26Oct 26ATTOHigh $52Median $45Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $30Median $45High $52

The green dot is the last close — the median target sits +175.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
31 Aug 2026CitigroupInitiatesBuy—
31 Aug 2026Leerink PartnersInitiatesOutperform—
31 Aug 2026LifeSci CapitalInitiatesOutperform—
31 Aug 2026Morgan StanleyInitiatesOverweight—
31 Aug 2026RBC CapitalInitiatesOutperform—
15 Aug 2022Barrington ResearchMaintainsOutperform$32 → $15
5 July 2022Goldman SachsMaintainsNeutral$28 → $14
21 Sept 2021Goldman SachsUpgradeNeutral$11 → $30
25 Nov 2020BairdMaintainsOutperform—
25 Nov 2020Bank of AmericaMaintainsNeutral—
25 Nov 2020Barrington ResearchInitiatesOutperform—
25 Nov 2020Credit SuisseDowngradeNeutral—
25 Nov 2020Goldman SachsDowngradeSell—
25 Nov 2020Morgan StanleyDowngradeEqual-Weight—
30 Apr 2020Goldman SachsDowngradeSell—
5 June 2019Morgan StanleyDowngradeEqual-Weight$8.00 → $3.00
8 Nov 2018BairdMaintainsOutperform$10 → $8.00
30 July 2018BairdMaintainsOutperform$12 → $10
3 Apr 2018Goldman SachsInitiatesNeutral—
21 Mar 2018BairdMaintainsOutperform$14 → $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATTO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ATTO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

ATTO vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110Sep 26Oct 26ATTOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATTO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Attovia Therapeutics, Inc. (ATTO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.9×

Cheaper than 92% of US stocks

Price / sales
413.7×

Cheaper than 2% of US stocks

Price / book
−4.8×

Cheaper than 97% of US stocks

EV / EBITDA
−11.9×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−99.9%

Higher than 2% of US stocks

Gross margin
—
Operating margin
−4845.1%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
56.7%

Higher than 94% of US stocks

Return on assets
−36.7%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Attovia Therapeutics, Inc. (ATTO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Attovia Therapeutics, Inc. has a market value of $744.6M and an enterprise value of $897.0M.

  • Revenue in the twelve months to 30 June 2026: $450K.

  • Net income over the same four quarters: −$68.9M, a −15318.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.37.

  • Shares outstanding: 43.0M.

  • Trailing P/E: −6.9×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Attovia Therapeutics, Inc. employs 44 people — $10K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

ATTO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATTOAttovia Therapeutics, Inc.$744.6M
0
ACHVAchieve Life Sciences, Inc.$738.1M
30
DNAGinkgo Bioworks Holdings, Inc.$734.5M
38
GYREGyre Therapeutics, Inc.$753.7M
45
OBXObsidian Therapeutics, Inc.$755.5M
59
ANNXAnnexon, Inc.$758.3M
38
APMDApnimed, Inc.$758.4M
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Attovia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATTO news & analysis

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

GlobeNewsWire · 28 Sept 2026positive

Attovia Therapeutics announced it will present new clinical, translational, and preclinical data across its pipeline, including ATTO-1310 and ATTO-2306, at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference 2026.

Why it matters — Investors tracking ATTO would care because upcoming presentations of pipeline data at major dermatology conferences could provide new insight into the company's development programs.

Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Attovia Therapeutics, Inc. (ATTO) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha.

Why it matters — ATTO watchers would care because the transcript offers insight into the company's presentation and messaging delivered at a major healthcare investment conference.

FAQ

Frequently asked questions about ATTO stock

What is the ATTO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Attovia Therapeutics, Inc. have a median 12-month price target of $45, with estimates ranging from $30 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATTO stock a buy right now?

Of the 5 analysts covering Attovia Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Attovia Therapeutics, Inc. 0 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATTO?

As at 8 Oct 2026, Attovia Therapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (48 of 100).

Will ATTO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +175.9% from the last close, and Ticker Nerd's factor model ranks Attovia Therapeutics, Inc. 0 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATTO stock forecast for 2030?

No analyst covering Attovia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATTO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $52 over the next 12 months.

What does Attovia Therapeutics, Inc. do?

Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases.

What is the latest news on ATTO?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026". Attovia Therapeutics announced it will present new clinical, translational, and preclinical data across its pipeline, including ATTO-1310 and ATTO-2306, at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference 2026.

Company

About Attovia Therapeutics, Inc.

Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases. The company’s core work centers on its ATTOBODY platform, which is designed to create multispecific protein therapies that target multiple disease pathways involved in inflammation and immune dysfunction. Its current pipeline includes candidates for dermatology conditions such as atopic dermatitis and chronic pruritus, as well as gastroenterology and inflammatory disorders, including inflammatory bowel disease. Attovia Therapeutics Inc. develops therapeutic programs aimed at areas with significant unmet medical need, using a platform-based approach intended to improve specificity and broaden treatment options across several disease areas. The company is based in San Carlos, California.

CEO Mr. Tao Fu M.B.A., M.S. · 44 employees · United States · https://www.attovia.com